Drugs / CT-01
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06994572 | May 2025 → Apr 2029 expected | hepatocellular carcinoma | Captor Therapeutics S.A. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06994572 ↗ |
| Modality | Small molecule | “Investigational small-molecule degrader targeting transcription factors in HCC.” NCT06994572 ↗ |
| Route | Oral | “Subjects receive CT-01 and everolimus orally once daily in 28-day cycles” NCT06994572 ↗ |